WSGR logoWSGR logo

The unique history of Wilson Sonsini Goodrich & Rosati closely traces the birth and evolution of Silicon Valley.

For more than 60 years, Wilson Sonsini has represented technology pioneers associated with virtually every milestone innovation, as well as life sciences trailblazers shaping the future of healthcare.

Today, the firm is synonymous with ushering promising, innovative companies through their business life cycle.

Read More About Us

Wilson Sonsini secured a jury trial win for Google in a case alleging misuse of advertising technology.

Click for additional details.
Careers

We look for the best and brightest of tomorrow and develop careers from the ground up.

News and Featured Insights

Alerts
SCOTUS Ruling Calls into Question EU-U.S. Personal Data Flows
Podcasts
NextGen VC Podcast – Why the Future of Biotech Starts with the Brain
News Articles
Wilson Sonsini Attorneys Named to 2026 Lawdragon 500 Leading Energy Lawyers Guide
Leading Matters
Client Highlights
Wilson Sonsini Advises Crinetics on Patent Matters Related to $10 Billion Acquisition by Vertex
On July 6, 2026, Vertex Pharmaceuticals and Crinetics Pharmaceuticals, a global pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases, announced that the companies have entered into a definitive agreement under which Vertex will acquire Crinetics for $85.00 per share in cash, for a total equity value of approximately $10 billion, or approximately $8.8 billion net of estimated cash acquired. Wilson Sonsini Goodrich & Rosati is patent counsel to Crinetics and advised the company on patent matters related to the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises TwelveLabs on $100 Million Series B
On July 1, 2026, TwelveLabs, a leading video intelligence company, announced it has raised $100 million in Series B funding. The round was co-led by NEA and NAVER Ventures with participation from Amazon, Radical Ventures, Korea Investment Partners, Index Ventures, Quadrille Capital, and Red Bull Ventures. Wilson Sonsini Goodrich & Rosati advised TwelveLabs on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Vicus Ventures on Fund I Launch
On June 30, 2026, Vicus Ventures closed Fund I, a $55 million debut seed fund, with a strategic group of 55 limited partners including General Catalyst, Bain Capital, and Kleiner Perkins. Wilson Sonsini Goodrich & Rosati served as counsel to Vicus Ventures in connection with the launch.
Learn More
Client Highlights
Wilson Sonsini Advises Hera on $27 Million Series A
On June 25, 2026, Hera, the company solving eldercare with human-centric AI, announced it has raised $27 million in Series A funding. The round was led by Bain Capital Ventures with continued participation from Accel. Wilson Sonsini Goodrich & Rosati advised Hera on the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises m3ter on Acquisition by Salesforce
Wilson Sonsini advised m3ter, a leading metering and rating platform purpose-built for consumption-based monetization, on its acquisition by Salesforce.
Learn More
Client Highlights
Wilson Sonsini Advises Kai Health on $4.8 Million Seed Round
On June 29, 2026, Kai Health, an AI-powered performance improvement platform for emergency medicine, announced a $4.8 million seed round led by Distributed Ventures. Wilson Sonsini Goodrich & Rosati advised Kai Health on the transaction.
Learn More
See More Leading Matters
The Life Sciences Report – June 2026

This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025.

Read More
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.